Skip to content

NeuroQ 3.8

by Syntermed Incorporated

NeuroQ 3.8 is a medical device (FDA Class II; FDA product code KPS, System, Tomography, Computed, Emission) made by Syntermed Incorporated, cleared under FDA 510(k) K130451 on 17 May 2013 and listed in FDA GUDID since 12 Nov 2020 (UDI-DI B133NEUROQ300), active as of 23 Oct 2026.

Active United States. Also listed in GUDID (US).

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 23 Oct 2026

Documents

510(k) K130451

FDA submission, from GUDID

Trust

Unverified

Source GUDID, synced 23 Oct 2026.

Regulatory status

as of registry sync 23 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesGUDID listing NumberB133NEUROQ300 UDI-DI Date12 Nov 2020ListedStatusListed GUDID: in commercial distribution
United StatesFDA 510(k)SESE from GUDID Substantially Equivalent · Traditional NumberK130451 Date17 May 2013DecidedStatusActive

Official records

From the FDA record

Device description
NeuroQ™ has been developed to aid in the assessment of human brain scans through quantification of mean pixel values lying within standardized regions of interest, and to provide quantified comparisons with brain scans derived from FDG-PET studies of defined groups having no identified neuropsychiatric disease or symptoms, i.e., asymptomatic controls (AC). The Program provides automated analysis of brain PET scans, with output that includes quantification of relative activity in 240 different brain regions, as well as measures of the magnitude and statistical significance with which activity in each region differs from mean activity values of brain regions in the AC database. The program can be used to compare activity in brain regions of individual scans between two studies from the same patient, between symmetric regions of interest within the brain PET study, and to perform an image fusion of the patients PET and CT data. The program can also be used to for assisting in the assessment of prognosis in patients undergoing dementia evaluation with respect to the likelihood of progression of symptomatic disease, to provide analysis of amyloid uptake levels in the brain, and to evaluate and to provide a quantitative analysis of uptake levels in basal ganglia structures of the brain. The program processes the studies automatically, however, user verification of output is required and manual processing capability is provided.
MRI safety
Labeling does not contain MRI Safety Information
Natural rubber latex
No latex statement on the label
Sterility
Supplied non-sterile

From the GUDID record (AccessGUDID), as read on 23 Oct 2026, as the labeller entered it.

Across registries

2 registries list this device

  • FDA 510(k) K130451 decided 17 May 2013 Active
  • FDA GUDID UDI-DI B133NEUROQ300 listed 12 Nov 2020 Listed

Timeline

2 dated events

  1. Cleared FDA 510(k) K130451
  2. Listed FDA GUDID B133NEUROQ300

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

GUDID

Trade name
NeuroQ
Generic name
Multidisciplinary medical image management software
Model / reference
3.8
Primary DI / UDI-DI
B133NEUROQ300
510(k) Number
FDA product code
KPS
GMDN term
Multidisciplinary medical image management software
Device class
Class II
Regulation number
892.1200
GUDID distribution status
In Commercial Distribution

Similar devices

Other devices filed under FDA product code KPS (System, Tomography, Computed, Emission).

Other devices from Syntermed Incorporated

See all devices from Syntermed Incorporated →

Properties

  • Single use
  • Prescription use
Other properties (13, all answered No)